OLMA
Olema Pharmaceuticals, Inc.
NASDAQ · Healthcare · Biotechnology · US
$10.75
+0.19%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−2.4x
Market Cap
$940.60M
MomentumView details →
1D Return
+0.19%
YTD Return
−57.12%
RSI (14)
46.7
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−2.4x
Market Cap
$940.60M
RSI (14)
46.7
MomentumView details →
1D Return
+0.19%
YTD Return
−57.12%
SummaryUpdated Jun 1, 2026
Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) is a clinical-stage biopharmaceutical company founded in 2006 and headquartered in San Francisco, California. Originally incorporated as CombiThera, Inc., the company changed its name to Olema Pharmaceuticals in March 2009 and went public in November 2020. Olema focuses exclusively on developing innovative therapies for women's cancers, particularly breast cancer, with its lead drug candidate currently in Phase 1/2 clinical trials.
Similar companies
Latest newsMore news →
Olema Pharmaceuticals appointed Jason O'Byrne as Chief Financial Officer, principal financial officer and principal accounting officer, effective as of the announcement date.23d agoOlema Pharmaceuticals completed enrollment in its pivotal Phase 3 OPERA-01 trial for breast cancer treatment, with top-line data expected in Q1 2027.24d ago